Wittenberg C, Rosenfeld J B
Hypertension Clinic, Beilinson Medical Center, Petah Tikva, Israel.
Am J Hypertens. 1991 Feb;4(2 Pt 2):191S-193S. doi: 10.1093/ajh/4.2.191s.
The renal effects of a single oral dose of placebo v a new dihydropyridine calcium antagonist, isradipine, were investigated in 12 patients with mild-to-moderate essential hypertension. Six patients (group A) had normal creatinine concentrations greater than 1.6 mg/dL. Patients maintained a constant daily intake of approximately 120 mmol of sodium and 50 mmol of potassium. Measurements were taken at 30, 60, and 90 min after drug administration. Results indicated that isradipine at a dose of 5 mg once daily produced significant antihypertensive and renal responses. In conclusion, there is therapeutic benefit with isradipine independent of the status of renal function.
在12例轻至中度原发性高血压患者中，研究了单次口服安慰剂与一种新型二氢吡啶类钙拮抗剂伊拉地平的肾脏效应。6例患者（A组）肌酐浓度正常，大于1.6mg/dL。患者每日维持约120mmol钠和50mmol钾的恒定摄入量。在给药后30、60和90分钟进行测量。结果表明，每日一次5mg剂量的伊拉地平产生了显著的降压和肾脏反应。总之，伊拉地平具有治疗益处，与肾功能状态无关。
